Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <?7% are associated with lower major cardiovascular events. American heart journal White, H. D., Stewart, R. A., Dalby, A. J., Stebbins, A., Cannon, C. P., Budaj, A., Linhart, A., Pais, P., Diaz, R., Steg, P. G., Krug-Gourley, S., Granger, C. B., Hochman, J. S., Koenig, W., Harrington, R. A., Held, C., Wallentin, L., STABILITY Investigators 2020; 225: 97–107

Abstract

BACKGROUND: In patients with stable coronary heart disease, it is not known whether achievement of standard of care (SOC) targets in addition to evidence-based medicine (EBM) is associated with lower major adverse cardiovascular events (MACE): cardiovascular death, myocardial infarction, and stroke.METHODS: EBM use was recommended in the STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY trial. SOC targets were blood pressure (BP) <140/90?mm Hg and low-density lipoprotein-cholesterol (LDL-C)?<100 mg/dL and <70 mg/dL. In patients with diabetes, glycosylated hemoglobin A1c (HbA1c)?

View details for DOI 10.1016/j.ahj.2020.04.004

View details for PubMedID 32480059